ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Oncology

FogPharma and ARTBIO Announce Partnership for the Development of Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies in Cancer Treatment

Wednesday, May 15, 2024

FogPharma® and ARTBIO, Inc. are collaborating to develop advanced therapies for various cancers. FogPharma, renowned for its innovative Helicon™ peptide platform, and ARTBIO, a leader in alpha radioligand therapies (ARTs), aim to create Helicon-enabled ARTs (HEARTs) to significantly improve patient outcomes.

By combining FogPharma's Helicon platform, allowing precise modification of peptides, with ARTBIO's AlphaDirect™ platform utilizing the potent isotope 212Pb, the collaboration seeks to develop next-generation ARTs. These therapies offer ideal tumor-targeting properties, with 212Pb's short half-life delivering maximum energy to tumors and enabling imaging with SPECT/CT.

FogPharma's CEO, Mathai Mammen, M.D., Ph.D., emphasized the potential of their AI-enabled platform to revolutionize cancer treatment by precisely targeting proteins both inside and outside cells. ARTBIO's CEO, Emanuele Ostuni, Ph.D., highlighted the promise of alpha radioligand therapy and 212Pb in treating solid tumors.

Both companies will contribute equally to research, development, and commercialization efforts, with specific financial terms remaining undisclosed.

 

Source: businesswire.com

magazine-slider-img
Oliver Healthcare Packaging Pharmaceutical SolutionsThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing Pharma
cytiva